Use of Novel oral anticoagulants (NOACs) in patients with risk of stroke in non valvular Atrial Fibrillation (AF)

Fawad Farooq*1, Muhammad Hashim1, Musa Karim1 & Ali Yasir2

1National Institute of Cardiovascular Disease (NICVD), Karachi, Pakistan
2Clinical Research & Pharmacovigilance, TSCL (Searle), Pakistan

*Corresponding Author Email ID: drfawadfarooq@yahoo.com

Received 6/12/17; Accepted 20/12/17; First Published 30/12/17

Abstract

Background: Warfarin was used for decades to prevent stroke in high risk AF patients, recent guidelines and published data is recommending use of NOACs like Rivaroxaban as an alternative to Warfarin. Its use is increasing world over because of its predictable action, less food and drug interaction and no need of monitoring for dose adjustments, considering these facts we planned to conduct a study to see the frequency of use of Rivaroxaban in our local population of AF patients with risk of stroke calculated by CHA2DS2-VASc score.

Method: This cross-sectional study was done at National Institute of Cardiovascular disease (NICVD) from May 2017 to September 2017 included 137 non-valvular AF patients with high risk of stroke calculated by applying CHA2DS2-VASc score more than or equal to 2. Clinical details and information about anticoagulant medications prescribed to them was also obtained. SPSS 19 was used for the analysis, descriptive statistics such as mean ±SD, frequency and percentages were calculated. Z-test, t-test, and chi-square test were used for the assessment and comparison of data. Two sided p-value of 0.05 was considered for statistical significance.

Results: Total 137 patient were included 50.4% (69) were male, 104 (75.91%) out of 137 were on Anticoagulant therapy, with 86 (62.77%) were on Warfarin and only 18 (13.14%) were taking Rivaroxaban.

Conclusion: Our study showed very small percentage of non valvular AF patients with risk of stroke were prescribed Rivaroxaban. It’s important to update our treating Physicians about this novel agent which is shown to be equally effective and safe in comparison to warfarin, and easy to prescribe without monitoring to reduce stroke risk.

Keywords

Novel oral anticoagulants (NOACs), Rivaroxaban, Non valvular atrial fibrillation

Introduction

Vitamin K antagonist like warfarin is recommended for years1–3 for prevention of stroke in high risk non-valvular Atrial Fibrillation (AF) patients. Its benefits are related to achieving an optimal level of anticoagulation, considering its narrow therapeutic index, food and drug interactions, with frequent monitoring of International Normalization Ratio (INR) for dose adjustments leads to difficulty in starting and continuing this drug in clinical practice even in conditions where its indicated4–6.

NOACs like Rivaroxaban, have more predictable anticoagulant effects, lesser food and drug interactions in comparison to vitamin K antagonists7, 8. All recent guidelines are considering Rivaroxaban to be a substitute to Warfarin in non-valvular AF patients with risk of stroke as it is found

Fawad Farooq
to be non-inferior in effectivity and safety as Warfarin in a number of recent clinical trials 9-12. One local study done by Ikramullah et al. showed only 27.5% of AF patients with high risk of stroke according to CHA2DS2VASc scoring system were treated with oral anticoagulation and all of them were taking Warfarin, it included two valvular patients as well13. This shows an inhibition towards prescribing oral anticoagulants in these high risk patients probably due to limitation we have with Warfarin use, as at present (NOACs) like Rivaroxaban is available in our country so we planned to conduct a study to see the present frequency of its use in Non-valvular AF patients with high risk of stroke.

**Methodology**

This cross-sectional study was conducted at National Institute of Cardiovascular Disease (NICVD) Karachi, Pakistan from May 2017 to September 2017 after getting approval of ethical review committee. Admitted or out patients above 20 years of age, with ECG evidence of paroxysmal, persistent or permanent Atrial fibrillation (AF) without any structural heart defect like hypertrophic and restrictive cardiomyopathy, constrictive pericarditis, valvular or congenital heart disease, having no evidence of thyroid disease or malignancy and without indications of anticoagulation other than AF and at high risk of stroke (CHA2DS2 VASc Score of more than or equal to 2) were selected. Informed consent was taken and all patients were inquired about their baseline clinical characteristics and Antithrombotic treatment they are prescribed. The CHA2DS2-VASc score was calculated by assigning 1 point each for Congestive Heart Failure (left ventricular ejection fraction [LVEF] ≤40%), hypertension, diabetes, vascular disease, age 65 years, and female gender, and 2 points for past history of thromboembolism(TE)/Transient Ischemic Attack (TIA)/stroke and for age ≥75 years. Information about different types of Antithrombotic therapies or medication like warfarin, (NOACs) like Rivaroxaban, etc. was also obtained from all patients.

**Statistical Analysis:**

Statistical package for social sciences (SPSS 21) was used to analyze the data. Mean ± SD was calculated for quantitative variables and frequency and percentages for categorical variables. Z-test or t-test was applied to test the hypothesis of equality of proportions or mean. Two-sided p-value of <0.05 was taken as criteria for statistical significance.

**Results**

This study includes 137 consecutive selected patients with high risk of stroke (CHA2DS2 VASc Score of more than or equal to 2), presented in outpatients department and admitted to National Institute of Cardiovascular Diseases (NICVD), Karachi Pakistan. Out of 137 patients 50.4% (69) were male, mean age 62.08 ± 10.91 years. Hypertension, CHF ≤ 40%, vascular disease, diabetes, and stroke / TIA / TE were observed in 68.61%, 61.31%, 47.45%, 21.9%, and 19.71% respectively. All baseline characteristics of patients are summarized in Table 1.

| Table 1 : Baseline Characteristics of the patients |
|---------------------------------------------------|
| Figures: n [column % ] or Mean ± SD | Total (n = 137) | Gender | **p-value** |
|------------------------------------------|-----------------|--------|-------------|
| Age                                      | 62.08 ± 10.91   | 63.46 ± 10.6 | 60.68 ± 11.12 | 0.135 |

Fawad Farooq
CHA2DS2 VASc score is significantly higher in females as compared to male patients $3.75 \pm 1.45$ vs. $3.3 \pm 1.15$ with p-value = 0.048. Although no statistically significant gender difference is observed in distribution of CHA2DS2 VASc score. Majority of the patients were found to have CHA2DS2 VASc score in range of 2 to 4, CHA2DS2 VASc score of 5, 6, 7, and 8 was observed in $12.41\%$, $4.38\%$, $2.92\%$, and $0.73\%$ respectively. Further details of the score in different gender is elaborated in table 2.

### Table 2: CHA2DS2 VASc score by gender

| CHA2DS2 VASc Score | Total (n = 137) | Male (n = 69) | Female (n = 68) | **p-value** |
|--------------------|----------------|--------------|----------------|-------------|
| 3.53 ± 1.32        |                | 3.3 ± 1.15   | 3.75 ± 1.45    | 0.048*      |
| 33 [24.09%]        | 18 [26.09%]    | 15 [22.06%]  |                | 0.581       |
| 44 [32.12%]        | 27 [39.13%]    | 17 [25%]     |                | 0.076       |
| 32 [23.36%]        | 13 [18.84%]    | 19 [27.94%]  |                | 0.208       |
| 17 [12.41%]        | 8 [11.59%]     | 9 [13.24%]   |                | 0.77        |
| 6 [4.38%]          | 2 [2.9%]       | 4 [5.88%]    |                | 0.393       |
| 4 [2.92%]          | 1 [1.45%]      | 3 [4.41%]    |                | 0.303       |
| 1 [0.73%]          | 0 [0%]         | 1 [1.47%]    |                | 0.312       |
| 0 [0%]             | 0 [0%]         | 0 [0%]       |                | -           |

*Statistically significant at 5% level of significance

Majority of our patients were taking Warfarin as an antithrombotic treatment while Rivaroxaban was prescribed to only $13.14\%$ (18) patients. No statistically significant difference in antithrombotic treatment was observed by gender. Summary of antithrombotic and antiplatelet prescribed to different gender is presented in table 3.
Table 3: Antithrombotic Treatment

|                     | Total (n = 137) | Male (n = 69) | Female (n = 68) | **p-value** |
|---------------------|-----------------|---------------|----------------|-------------|
| **Antithrombotic**  |                 |               |                |             |
| **Antiplatelet**    | 103 [75.18%]    | 58 [84.06%]   | 45 [66.18%]    | 0.185       |
| **Warfarin**        | 86 [62.77%]     | 40 [57.97%]   | 46 [67.65%]    | 0.208       |
| **NOAC (Rivaroxaban)** | 18 [13.14%]   | 9 [13.04%]    | 9 [13.24%]     | 0.88        |

*Statistically significant at 5% level of significance
**P-values are based on z-test

Discussion

Our study showed majority of our patients 104 (75.91%) out of 137 were on anticoagulation which in comparison to a local study done by Ikramullah et al in which only 27.5% patients were taking anticoagulation, was encouraging as most of our patients are selected from dedicated Anticoagulant clinic, most of them 86 (62.77%) were on Warfarin and only 18 (13.14%) were taking Rivaroxaban. Recent guidelines are preferring use of Rivaroxaban over warfarin and this strategy is implemented although at a modest level in a number of countries. In our study the number of patients on Rivaroxaban was very low probably because of the common documented barriers like concerns of bleeding and some others reasons like cost to translate guidelines recommendations into clinical practice. Our study population was small and patients were included from a tertiary care cardiac center so cant translate the real status of management of such patients in community where incidence and prevalence of AF is on rise with increasing age and hypertension.

Conclusion

Our study showed very small percentage of our AF patients with high risk of stroke were prescribed Rivaroxaban which is a very good alternative to conventional warfarin therapy in reducing stroke risk. It’s important to propagate updated knowledge regarding NOACs use in our medical community and a large local trial can be done to ensure safety and efficacy in our local population to enhance confidence of treating Physicians.

Conflicts of Interests

None.

Acknowledgement

Authors are thankful to the all NICVD study staff members for assistance in conducting the study.

Funding

None.

References

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Annals of internal medicine. 1999 Oct 5;131(7):492-501.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Antithrombotic Therapy in Atrial Fibrillation. Annals of internal medicine. 2007 Jun 19;146(12):857-67.
3. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. CHEST Journal. 2004 Sep 1;126(3_suppl):429S-56S.
4. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, Kemp S, Hall EA, Morton DJ, Vlasses PH. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals.

Fawad Farooq
5. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Annals of internal medicine. 1999 Dec 21;131(12):927-34.

6. Piccini JP, Hernandez AF, Zhao X, Patel MR, Lewis WR, Peterson ED, Fonarow GC, Committee GW. Quality of care for atrial fibrillation among patients hospitalized for heart failure. Journal of the American College of Cardiology. 2009 Sep 29;54(14):1280-9.

7. Kubitz D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. European journal of clinical pharmacology. 2005 Dec 1;61(12):873-80.

8. Kubitz D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Current medical research and opinion. 2008 Oct 1;24(10):2757-65.

9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 2009; 361: 1139–1151.

10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC. Apixaban versus warfarin in patients with atrial fibrillation n New England Journal of Medicine. 2011 Sep 15; 365(11):981-92.

11. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Poalini JF, Berkowitz SD, Fox KAA, Cathiff RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.

12. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JL, Spinar J, Ruzyllo W. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2013 Nov 28;369(22):2093-104.

13. Ullah I, Ahmad F, Ahmad S, Hayat Y. Atrial fibrillation and stroke prevention practices in patients with candidacy for anticoagulation therapy. Journal of Ayub Medical College Abbottabad. 2015 Sep 30:27(3):669-72.

14. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–2747. doi: 10.1093/eurheartj/ehs253.

15. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016; 37: 2893–2962.

16. Potpara TS, Dan GA, Trendafilova E, Goda A, Kusljugic Z, Manola S, Music L, Musetescu R, Badila E, Mitic G, Paparisto V. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan region: the BALKAN-AF survey. Scientific reports. 2016 Feb 12;6:20432.

17. Lip, Gregory YH, Stephan Windecker, Kurt Huber, Paulus Kirchhof, Francisco Marin, Jürriën M. Ten Berg, Karl Georg Haeseler et al. "Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart ..." European heart journal (2014): ehu298.

18. Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost. 2014 May 1;111(5):783-8.

19. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics–2013 update: A report from the American Heart Association. Circulation 2013; 127: e6 –e245.

20. Go AS, Hylek EM, Phillips KA, Chang Y, Renhaut LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama. 2001 May 9;285(18):2370-5.